Independent · Source-linked · Human-verified

What's the legal status, today?

“Legal” is rarely a clean yes or no - so we don't pretend it is. Peptlas is a neutral, independent reference that tracks the U.S. and international regulatory status of named compounds under FDA process - every entry sourced, dated, organized by name, and updated within 24 hours of any change we detect. We sell nothing. We just tell you where things actually stand.

Browse the atlasHow we track it

The FDA committee voted on July 23-24, 2026. It recommended six of seven peptides for the 503A list and rejected one. It is being widely reported as the FDA legalising them. It did not. The votes are advisory, the FDA has not acted, and not one of the seven is on the list today.

See every vote, and what it actually changed →

The atlas

Grouped by U.S. status - most time-sensitive first. Tap any compound for the full picture.

In limbo14Nominated or removed from a restricted list but NOT approved - the headline implies a change, but the legal reality did not move.

BPC-157

In limbo

Body Protection Compound 157 · Bepecin · PL 14736

PCAC recommended listing (8-6, Jul 23, 2026) - advisory only; still not on the 503A list

Changed 35 days ago 5 primary sources

CJC-1295

In limbo

Modified GRF 1-29 · DAC:GRF · CJC-1295 DAC

PCAC voted against listing (Dec 2024); off Category 2, not on the 503A list

Changed Dec 4, 2024 2 primary sources

Emideltide (DSIP)

In limbo

Delta sleep-inducing peptide · DSIP · Emideltide acetate

PCAC voted against listing (6-7, Jul 24, 2026); not on the 503A list

Changed 34 days ago 5 primary sources

Epitalon

In limbo

Epithalon · Epithalone · AEDG

PCAC recommended listing (reported 7-4, Jul 24, 2026) - advisory only; still not on the 503A list

Changed 34 days ago 5 primary sources

GHK-Cu

In limbo

Copper tripeptide-1 · Copper peptide · GHK-copper

Injectable removed from Category 2, not on the 503A list; PCAC review expected before end of Feb 2027

Next Feb 28, 2027 · in 185 daysChanged Apr 22, 2026 1 primary source

Ipamorelin

In limbo

Ipamorelin acetate

PCAC voted against listing (Oct 2024); off Category 2, not on the 503A list

Changed Oct 29, 2024 2 primary sources

KPV

In limbo

Lysine-proline-valine · Lys-Pro-Val · KPV acetate

PCAC recommended listing (8-6, Jul 23, 2026) - advisory only; still not on the 503A list

Changed 35 days ago 5 primary sources

Melanotan II

In limbo

MT-II · MT-2 · Melanotan-2

Off Category 2, not on the 503A list; PCAC review expected before end of Feb 2027

Next Feb 28, 2027 · in 185 daysChanged Apr 22, 2026 1 primary source

MOTS-c

In limbo

MOTs-C · Mitochondrial-derived peptide · MOTS-c acetate

PCAC recommended listing (7-5, Jul 23, 2026) - advisory only; still not on the 503A list

Changed 35 days ago 5 primary sources

NAD+

In limbo

Nicotinamide adenine dinucleotide · NAD · β-NAD

Not on the finalized 503A list; no federal ban; compounded in a gray area

Changed Sep 5, 2019 2 primary sources

Selank

In limbo

Selank acetate · TP-7

Removed from Category 2 (2024); not on the 503A list; no scheduled review

Changed Sep 27, 2024 1 primary source

Semax

In limbo

Semax acetate

PCAC recommended listing (8-5, Jul 24, 2026) - advisory only; still not on the 503A list

Changed 34 days ago 4 primary sources

TB-500 (Thymosin Beta-4)

In limbo

TB-500 · Thymosin Beta-4 · TB-4

PCAC recommended listing (8-6, Jul 23, 2026) - advisory only; still not on the 503A list

Changed 35 days ago 4 primary sources

Thymosin Alpha-1

In limbo

Thymalfasin · Zadaxin · Tα1

Off Category 2, never in Category 1; PCAC declined Dec 2024

Changed Dec 4, 2024 3 primary sources
Restricted3Prescription-only, banned, controlled, or under active FDA enforcement.

Retatrutide

Restricted

LY3437943 · GIP/GLP-1/glucagon triple agonist · triple G

Investigational only - no approved form exists anywhere; cannot be compounded; FDA warning letters target sellers

Next Mar 31, 2027 · in 216 daysChanged Sep 9, 2025 3 primary sources

Semaglutide (compounded)

Restricted

Ozempic · Wegovy · compounded semaglutide

Enforcement discretion ended; routine compounding no longer permitted. 503B exclusion proposed - comments closed Jul 30, 2026, decision pending

Changed 28 days ago 2 primary sources

Tirzepatide (compounded)

Restricted

Mounjaro · Zepbound · compounded tirzepatide

Enforcement discretion ended; broad compounding no longer permitted. 503B exclusion proposed - comments closed Jul 30, 2026, decision pending

Changed 28 days ago 2 primary sources
Compounding-legal1On the FDA 503A bulk-substances list; a licensed pharmacy may compound it. This is not the same as being an FDA-approved drug.

Sermorelin

Compounding-legal

GRF 1-29 · Geref · Sermorelin acetate

Category 1 of the interim 503A list - compoundable with a prescription

Changed Feb 19, 2019 1 primary source

The five states

We never reduce this to “legal / illegal.” Every badge pairs a color with a word, so status is readable without relying on color.

Under review
Actively before the FDA advisory committee; a decision is pending and the status can move.
In limbo
Nominated or removed from a restricted list but NOT approved - the headline implies a change, but the legal reality did not move.
Restricted
Prescription-only, banned, controlled, or under active FDA enforcement.
Compounding-legal
On the FDA 503A bulk-substances list; a licensed pharmacy may compound it. This is not the same as being an FDA-approved drug.
Unscheduled
No specific federal action; unaddressed at this time.

Who runs this - and why it stays neutral

Peptlas is maintained by the Peptlas Research Team, an independent group. We sell nothing - no products, no affiliates, no sponsors - so we have no stake in what any status turns out to be. Every entry links to its primary source and carries a human-verified date, and every change is logged in the open. About us · how we track it · the public record.

Informational only - not medical or legal advice, and no health claim. Always confirm against the linked primary source. Full disclaimer.